☀️ Good morning.
Is your lab or company hiring? Tell me and I’ll include it in this newsletter.
You ask particularly after my health. I suppose that I have not many months to live; but, of course, I know nothing about it. I may add that I am enjoying existence as much as ever, and regret nothing.
—Henry David Thoreau
📰 Bioengineering in the News
Pitch: A machine-learning CRISPR approach for sustainable buildings on Mars. Money.
EX UTERO MICE: For a Nature study, researchers at the Weizmann Institute of Science grew mice in little bottles, ex utero. The mouse embryos developed up to the hind limb formation stage, and the researchers have grown more than 1,000 embryos using this method. The New York Times. Link (Also covered in Science, MIT Technology Review and Future Human.)
UK CRISPR NEWS: The UK is considering a departure from EU regulations on gene-edited food, opening the gates for CRISPR-edited crops. A government department “is proposing that gene-editing technology should not be regulated in the same way as GM, if it yields a result that could have been produced by conventional breeding,” according to reporting by Nature. Link
COSMETIC EVENT: An event, scheduled for March 24th at 4pm (GMT+1), will bring together synthetic biologists to talk about how recent research can be transferred to the cosmetic industry. It looks like registration is free. Link
SAVE THE OCEANS: Davey Ho (whose artwork has appeared in this newsletter) wrote a great piece about how synthetic biology can help with marine conservation. SynBioBeta. Link
MUSHROOM CLOTHES: Stella McCartney, in a collaboration with Bolt Threads, is launching shirt and pants made from Mylo (an engineered mushroom material.) The clothes are jet black, and look straight out of Star Trek. Vogue. Link
ALGAE-COATED CLOTHES: A French car company, called DS Automobiles, launched a four-piece fashion collection. The clothes are coated in living, photosynthetic algae, because…why not? Dezeen. Link
NEW TV SHOW: A new television series is in the works, “centered on the dangerous and life-affirming ways” that gene-editing can alter our world. George Church is involved. Deadline. Link
XPRIZE WINNERS: The XPrize has picked nine teams as winners of its $6 million “COVID diagnostics competition.” Winning ideas included smell machines and RNA-based tests for SARS-CoV-2. Fierce Biotech. Link
LAB BLASTOIDS: For multiple studies, researchers coaxed “lab-grown human cells to form clusters” similar to blastocysts. The breakthrough could help scientists better study human fertility and embryo development. Science. Link (Also covered in Genetic Engineering and Biotechnology News.)
SYNBIO STOCK: After Amyris, a synthetic biology company, switched from biofuels to the personal care space, their stock went up 10x. Forbes. Link
BABY ANTIBODIES: An American woman who received a dose of the coronavirus vaccine while 36 weeks pregnant is the first to give birth to a baby known to have antibodies against the novel coronavirus. The Guardian. Link
PAPER DEAL: The University of California and Elsevier have finally agreed to an “open-access deal.” The Scientist. Link
LUNAR ARK: This is bizarre: Scientists want to store the DNA sequences for millions of species on the moon, using hollowed out tunnels to protect them from the insults of space. Live Science. Link
DNA DETECTIVES: As DNA databases expand, and computational tools improve, two researchers ask: Will forensic DNA become better at finding criminals? Advanced Science News. Link
Bluebird bio (Cambridge, MA), the gene therapy company behind the halted sickle cell clinical trial, has released encouraging results for their cerebral adrenoleukodystrophy therapy. The company’s chief medical officer has also quit. Fierce Biotech. Link
CytoSeek (Bristol, UK), a startup biotech company, has raised nearly $5 million in a round of funding. The company is developing a protein “coat” that binds to immune cells and gives them enhanced therapeutic properties. Fortune. Link
Navega Therapeutics (San Diego, CA), a UCSD spinout company, is developing gene therapies for pain. The company’s founders published a study, last week, in which they used CRISPR to repress the gene that encodes Nav1.7, thus reducing pain in mice without opioids. Fierce Biotech. Link
Twist Bioscience, the DNA synthesis company, has four job openings that they’re hoping to fill. Automation/Senior Automation Engineer (Link) Senior Full Stack Engineer (Link) Scientist, Synthetic Biology (Link) Scientist, SVL Product Development (Link)
Have a good weekend,
Thanks for reading Cell Crunch, part of Bioeconomy.XYZ. If you enjoy this newsletter, please share it with a friend or colleague. A version of these newsletters is also posted on Medium. Reach me with tips and feedback on Twitter @NikoMcCarty or via email.